Novartis AG at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Hi, everyone. Welcome to our noon session today. My name is Daina Graybosch. I'm one of the senior analysts here at Leerink, and I'm really delighted to host Novartis, where we have Rob Kowalski who leads Regulatory Affairs and is the U.S. Head of Global Drug Development.
Thank you so much for joining us today.
Thanks, Daina. Happy to be here with. Looking forward to the opportunity. Thank you.
Questions & Answers
We're going jump right into the questions, but first, some housekeeping. (Operator Instructions) Although, of course, I could spend probably 2 hours on my own questions.
So with that, let's jump right in. Impressively, Entresto has been one of Novartis's pretty key drugs, bringing in $2.5 billion in 2020 and growing 44%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
